In this work, we report the conversion of carbon dioxide (CO) gas into graphene on copper foil by using a thermal chemical vapor deposition (CVD) method assisted by hydrogen (H) plasma pre-treatment. The synthesized graphene has been characterized by Raman spectroscopy, X-ray diffraction, scanning electron microscopy, and transmission electron microscopy. The results show the controllable number of layers (two to six layers) of high-quality graphene by adjusting H plasma pre-treatment powers (100-400 W). The number of layers is reduced with increasing H plasma pre-treatment powers due to the direct modification of metal catalyst surfaces. Bilayer graphene can be well grown with H plasma pre-treatment powers of 400 W while few-layer graphene has been successfully formed under H plasma pre-treatment powers ranging from 100 to 300 W. The formation mechanism is highlighted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412882 | PMC |
| http://dx.doi.org/10.3390/membranes12080796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.
Eur J Nucl Med Mol Imaging
January 2025
Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
Purpose: Prostate-specific membrane antigen (PSMA) radioligand therapy is a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Several beta or alpha particle-emitting radionuclide-conjugated small molecules have shown efficacy in late-stage mCRPC and one, [[177Lu]Lu]Lu-PSMA-617, is FDA approved. In addition to tumor upregulation, PSMA is also expressed in kidneys and salivary glands where specific uptake can cause dose-limiting xerostomia and potential for nephrotoxicity.
View Article and Find Full Text PDFBlood levels of Mycobacterium tuberculosis (Mtb)antigen-triggered immune markers in people exposed to tuberculosis with regard to Mtb infection status and receipt of tuberculosis preventive therapy.
Tuberculosis (Edinb)
December 2024
Clinical Infection Medicine, Department of Translational Medicine, Lund University, Ruth Lundskogs gata 3, SE214 28, Malmö, Sweden.
Background: Interferon-γ release assays (IGRAs) for tuberculosis infection (TBI) cannot distinguish different stages of the TBI spectrum (including spontaneously cleared infection). We investigated patterns of Mtb-specific blood mediators in people with and without TBI during tuberculosis preventive therapy (TPT).
Methods: Individuals with likelihood of recent Mtb exposure, aged 15-25 years, with valid IGRA results, in whom tuberculosis (TB) had been excluded, were included.
Enhancement of vindoline and catharanthine production in Catharanthus roseus by LED light and plasma activated water.
PLoS One
December 2024
Department of Agricultural and Food Sciences (DISTAL), University of Bologna, Bologna, Italy.
This study aimed to increase the concentrations of vindoline (VDL) and catharanthine (CAT) in Catharanthus roseus plants cultivated in an indoor farming system using artificial lighting and plasma-activated water (PAW). After a 61-days pre-treatment period under fluorescent lamps, plants were exposed to four treatments: white light (W) from the same fluorescent lamps, red light (R) from LEDs, W with PAW, and R with PAW. These combinations were evaluated at two sampling times: 45 days (T1) and 70 days (T2) after the end of pre-treatment (DAP).
View Article and Find Full Text PDFOptimizing the cumulative cisplatin dose for concurrent chemoradiotherapy beneficiaries among elderly nasopharyngeal carcinoma patients: a real world study.
Sci Rep
December 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, Guangdong, China.
This study aimed to find a safe and effective cumulative cisplatin dose (CCD) for concurrent chemoradiotherapy (CCRT) beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients. A total of 765 elderly (≥ 60 years old) NPC patients treated with cisplatin-based CCRT and IMRT-alone from 2007 to 2018 were included in this study. RPA-generated risk stratification was used to identify CCRT beneficiaries.
View Article and Find Full Text PDFDual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.
Mol Clin Oncol
February 2025
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
We have been exploring biomarkers that could help physicians select the appropriate opioid for individualized treatment of cancer pain. Recently, we identified a single nucleotide polymorphism (SNP) of (rs17809012) as one such biomarker that was significantly associated with the analgesic effect of morphine. The current study measured the plasma concentrations of chemokines/cytokines in pre-treatment plasma samples of a total of 138 patients who were randomized to receive morphine (n=70) or oxycodone (n=68).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!